Last reviewed · How we verify

NCT07312305: SWIFT-IPF

Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)

Recruiting now Last updated 28 January 2026
What this trial tests

trial in Idiopathic Pulmonary Fibrosis in 100 participants. Currently enrolling.

Timeline
15 May 2025
Primary endpoint
15 May 2026
15 May 2027

Quick facts

Lead sponsorUniversity of Milan
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date15 May 2025
Primary completion15 May 2026
Estimated completion15 May 2027
Sites2 locations across Italy

Conditions studied

Sponsor

University of Milan

Who can join

18 and older, any sex, with Idiopathic Pulmonary Fibrosis or Small Airways Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing, and progressive lung disease of unknown cause, whose incidence increases proportionally from the age of 60. It is characterized by a poor prognosis. Antifibrotic therapy can slow the progression of the disease and reduce mortality, but the life expectancy is less than 7-10 years in the vast majority of patients with IPF. There are no studies in the literature that have evaluated the presence of small airway disease in patients with IPF prior to the initiation of pharmacological therapy, using the nitrogen washout test. This test is currently considered the only non-invasive method capable of detecting ventilation inhomogeneity and closing volume, which are indicators of small airway dysfunction. The investigators carried out an Italian prospective, observational, multicenter study with the primary aim to assess the prevalence of small airway disease measured by the nitrogen washout test (evaluating the following functional parameters: phase 3 slope, closing volume, closing capacity, closing volume/vital capacity, closing capacity/total lung capacity, and phase 4 slope) in a group of patients with IPF at the time of diagnosis, before the initiation of antifibrotic therapy. During outpatients visits clinical, functional and radiological data will be collected. Results will be compared to an healthy control group matched with IPF population. Variations in small airways disease parameters will be assessed after one year of antifibrotic treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

Other University of Milan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07312305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing